You are here: Industry Insights > MS

News List

Sanofi teams up with Denali in $1.125bn neurological and inflammatory development deal pharmafile
November 19, 2018
Sanofi has sealed the deal with Denali Therapeutics to leverage the latter’s small molecule candidates in the development of new therapies to tackle a variety of neurological
Novartis files MS drug siponimod in EU and US pharmatimes
October 11, 2018
Novartis is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy siponimod to treat secondary progressive forms of the disease.
NICE ‘no’ for Roche’s Ocrevus in primary progressive MS pharmatimes
July 03, 2018
The National Institute for Health and Care Excellence has concluded that Roche’s Ocrevus should not be funded on the NHS for the treatment of primary progressive multiple sclerosis (PPMS) in adults.
EMA confirms risks of MS drug Zinbryta pharmatimes
May 24, 2018
The Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that Zinbryta (daclizumab) “poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs.”
Netmeds appoints MS Dhoni as brand ambassador financialexpress
May 21, 2018
Online pharmacy Netmeds has appointed cricketer Mahendra Singh Dhoni as its brand ambassador. Commenting on the development,
Biogen’s First Quarter Driven by MS Drugs and Spinraza biospace
April 25, 2018
Biogen saw a strong first quarter with 11 percent growth in revenues to $3.1 billion, which were spurred by gains in spinal muscular atrophy (SMA) treatment Spinraza and multiple sclerosis treatment Tecfidera.
Relapsing MS Patients Who Switched to Aubagio® (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies biospace
April 24, 2018
Patients with relapsing multiple sclerosis who switched to Sanofi Genzyme's Aubagio® from interferon therapy experienced improvements in treatment satisfaction, according to investigational data from two clinical studies.
National MS Society Commits $14.2 Million to New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever biospace
April 18, 2018
The National Multiple Sclerosis Society has just committed more than $14.2 million to support 45 new MS research projects.
Surprise finding could lead to new MS treatments worldpharmanews
March 09, 2018
A surprise finding by medical scientists may lead to the development of a possible treatment for multiple sclerosis (MS)
Santhera’s Raxone fails in MS trial pharmatimes
March 07, 2018
Santhera has been hit with more bad news regarding its flagship mitochondrial disease therapy idebenone, after it failed to hit targets in a trial assessing its potential in multiple sclerosis.

Previous page 1 2 3 4 5 6 7 8 9 Next page